Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Brian Abrahams

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.

Investors Business Daily

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

Investors Business Daily

How IBD Stock Of The Day Vertex Is Stacking Up Billions In Potential Sales

Vertex is Wednesday's IBD Stock Of The Day. As the biotech eyes several blockbuster opportunities, VRTX stock is finding renewed support.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Investors Business Daily

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Investors Business Daily

IBD Stock Of The Day Vertex Pharma: Why Its 'Sandbox' Approach Is Unusual In Biotech

Vertex Pharmaceuticals is the IBD Stock Of The Day as VRTX stock climbs higher on expectations for its next act in gene editing.

Investors Business Daily

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug

Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.

Investors Business Daily

The Market Slumped Last Week; Why IBD Stock Of The Day Neurocrine Biosciences Didn't

Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.

Investors Business Daily

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

Investors Business Daily

IBD Stock Of The Day Incyte Nears Buy Point After Winning A First-Ever Approval

IBD Stock Of The Day Incyte just won U.S. approval for a new skin treatment, leading Incyte stock to flirt with a breakout.

Investors Business Daily

Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why

Biotech stock Pliant Therapeutics doubled Monday after the company unveiled positive midstage test results for a lung-disease treatment.

Investors Business Daily

Why Top-Notch Biotech Stock Vertex Pharmaceuticals Just Hit A Record

The FDA cleared Vertex to restart testing a diabetes treatment, and VRTX stock jumped to a fresh high Wednesday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

PTC Stock Has Gained 41% This Week Alone, And It's Still Sprinting

Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.

Investors Business Daily

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?

Crispr Therapeutics could have a "functional cure" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.

Investors Business Daily

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer

A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.

Investors Business Daily

Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug

Intercept sold the international rights to its liver-disease treatment, Ocaliva, for up to $450 million on Thursday, and ICPT stock soared.

Investors Business Daily

How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug

Medicare officially restricted use of Biogen's Alzheimer's treatment, Aduhelm, to patients enrolled in clinical studies.

Investors Business Daily

Biogen Snags Upgrade On Alzheimer's Hopes, And Then Announces Layoffs

Biogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer's treatments.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.